Critical

Scleroderma renal crisis

SRC · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Acute, often malignant hypertension with rapidly progressive AKI and thrombotic microangiopathy in systemic sclerosis, typically early diffuse disease. Prompt ACE inhibitor therapy is life- and kidney-saving and is the cornerstone of treatment.

Red flags

  • Rapidly rising creatinine with severe hypertension
  • Microangiopathic haemolytic anaemia with thrombocytopenia
  • Hypertensive encephalopathy or pulmonary oedema
  • Recent high-dose corticosteroid exposure
  • Normotensive renal crisis (worse prognosis)

Assessment

Differential diagnosis

  • Scleroderma renal crisis
  • Malignant hypertension from another cause
  • Thrombotic microangiopathy (TTP/aHUS)
  • ANCA-associated vasculitis (can overlap in scleroderma)
  • Acute glomerulonephritis
  • Drug-induced (high-dose corticosteroid-precipitated)

Investigations

  • Blood pressure (often markedly elevated; occasionally normotensive crisis)
  • U&E/creatinine trend, FBC (thrombocytopenia), blood film (schistocytes), LDH, haptoglobin
  • Urinalysis (mild proteinuria, few casts)
  • Renin (markedly elevated)
  • ANA/anti-RNA polymerase III, ANCA and anti-GBM (exclude overlap)
  • Renal biopsy only if diagnosis unclear (onion-skin vessels, TMA)

Management

  • Recognise the triad: new accelerated hypertension, rapidly rising creatinine and microangiopathic haemolysis in systemic sclerosis (especially early diffuse disease on steroids)
  • Start an ACE inhibitor immediately and titrate rapidly to control BP — do this even if renal function transiently worsens
  • Aim to lower BP steadily (e.g. by ~20 mmHg/day toward target) rather than precipitously
  • Add additional antihypertensives (calcium-channel blocker, others) if ACE inhibitor alone is insufficient — but never stop the ACE inhibitor
  • Avoid high-dose corticosteroids, which precipitate renal crisis
  • Support renal failure: manage fluid, electrolytes and start dialysis if needed (many recover function over months)
  • Distinguish from and exclude overlapping TTP/aHUS and vasculitis if the picture is atypical
  • Monitor haemolysis markers and platelet recovery
  • Continue the ACE inhibitor long-term even if dialysis is required — renal recovery can occur up to 1-2 years later
  • Manage as inpatient/HDU with close BP and renal monitoring
  • Treat the underlying systemic sclerosis with rheumatology input (avoiding steroids where possible)
  • Provide long-term nephrology and rheumatology follow-up

Drugs & doses

Captopril 6.25-12.5 mg PO, uptitrated rapidly every few hours to control BP (short-acting ACE inhibitor preferred for titration)
Enalapril/ramipril once converted from captopril for maintenance
Amlodipine 5-10 mg PO daily or other agent added if BP not controlled on ACE inhibitor
Labetalol/IV antihypertensive as adjunct in severe cases (never replacing ACE inhibitor)

Disposition

Admit (HDU/ICU) under nephrology with rheumatology; rapid ACE inhibitor titration. Dialysis as needed with long-term ACE inhibitor continuation and specialist follow-up.

Complications & pitfalls

  • Irreversible renal failure requiring dialysis
  • Hypertensive encephalopathy, heart failure
  • Microangiopathic haemolysis
  • Pericardial effusion/tamponade
  • Death if untreated

Exam pearls

  • ACE inhibitors are life-saving and must be continued even as creatinine rises or on dialysis
  • High-dose steroids precipitate scleroderma renal crisis — avoid them in at-risk scleroderma
  • Anti-RNA polymerase III antibody and early diffuse disease mark high risk
  • Renal recovery can occur months later — do not abandon the ACE inhibitor
  • A normotensive crisis exists and carries a worse prognosis

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.